According to Zhitong Finance App, Hanson Pharmaceuticals (03692) announced that on September 24, 2026, the Group's innovative drug HS-20093 (injectable Ruikang rivolutamab) marketing license application was accepted by the China National Drug Administration (NMPA) to treat osteosarcoma patients aged ≥12 years who have failed at least second-line treatment in the past. HS-20093 for injection is a B7-H3 targeting antibody-drug conjugate (ADC) independently developed by the Group.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.